First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.

被引：2
|
作者：
Soria, J.
De Braud, F. G.
Cereda, R.
Bahleda, R.
Delmonte, A.
Angevin, E.
Varga, A.
Noberasco, C.
Dall'O, E.
Lassau, N.
Dromain, C.
Bellomi, M.
Farace, F.
Bertolini, F.
Zucchetti, M.
Marsoni, S.
Camboni, M. G.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] European Inst Oncol, Milan, Italy
[3] EOS SpA, Milan, Italy
[4] SENDO, Milan, Italy
[5] Mario Negri Inst Pharmacol Res, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS149
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors
    Soria, J. C.
    De Braud, F.
    Cereda, R.
    Bahleda, R.
    Delmonte, A.
    Angevin, E.
    Varga, A.
    Noberasco, C.
    Dall'O', E.
    Lassau, N.
    Dromain, C.
    Bellomi, M.
    Farace, F.
    Bertolini, F.
    Zucchetti, M.
    Marsoni, S.
    Camboni, M. G.
    ANNALS OF ONCOLOGY, 2011, 22 : 40 - 40
  • [2] FIRST-IN-MAN STUDY OF E-3810, A NOVEL VEGFR AND FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Soria, J. C.
    Dienstmann, R.
    de Braud, F.
    Cereda, R.
    Bahleda, R.
    Hollebecque, A.
    Tabernero, J.
    Delmonte, A.
    Dromain, C.
    Lassau, N.
    Farace, F.
    Zucchetti, M.
    Marsoni, S.
    Camboni, M. G.
    ANNALS OF ONCOLOGY, 2012, 23 : 16 - 17
  • [3] Pharmacokinetics of the Novel FGFR and VEGFR Inhibitor, E-3810, in Patients with Advanced Solid Tumors Participating to a Phase I/II Trial
    Zangarini, M.
    Sala, F.
    Camboni, M. G.
    Cereda, R.
    Livi, V.
    Bahleda, R.
    Dienstmann, R.
    Delmonte, A.
    D'Incalci, M.
    Zucchetti, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 183 - 183
  • [4] SIGNIFICANT ANTITUMOR ACTIVITY OF E-3810, A NOVEL FGFR AND VEGFR INHIBITOR, IN PATIENTS WITH FGFR1 AMPLIFIED BREAST CANCER
    Dienstmann, R.
    Andre, F.
    Soria, J.
    Tabernero, J.
    De Braud, F. G. M.
    Cereda, R.
    Bahleda, R.
    Hollebecque, A.
    Delmonte, A.
    Camboni, M. G.
    ANNALS OF ONCOLOGY, 2012, 23 : 116 - 117
  • [5] First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Shen, Lin
    Gong, Jifang
    Huang, Cheng
    Ye, Chen Yang
    Yang, Li
    Sai, Yang
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
    Bello, Ezia
    Colella, Gennaro
    Scarlato, Valentina
    Oliva, Paolo
    Berndt, Alexander
    Valbusa, Giovanni
    Serra, Sonia Colombo
    D'Incalci, Maurizio
    Cavalletti, Ennio
    Giavazzi, Raffaella
    Damia, Giovanna
    Camboni, Gabriella
    CANCER RESEARCH, 2011, 71 (04) : 1396 - 1405
  • [7] First-in-human study of TAS-115, a novel oral MET/VEGFR inhibitor, in patients with advanced solid tumors.
    Matsubara, Nobuaki
    Shitara, Kohei
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ohno, Izumi
    Takahashi, Hideaki
    Bando, Hideaki
    Kojima, Takashi
    Fuse, Nozomu
    Yamazaki, Tomoko
    Hirayama, Naoki
    Fujita, Hidenori
    Nishida, Toshirou
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Chen, Yu-ling
    Jia, Ru
    Shen, Lin
    Wang, Jian
    Sai, Yang
    Qi, Chuan
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors.
    Aftimos, Philippe Georges
    Bechter, Oliver
    Awada, Ahmad
    Jungels, Christiane
    Dumez, Herlinde
    Huyvaert, Nathalie
    Costermans, Jo
    Lee, Chooi
    Meeus, Marie-Anne
    Burkard, Ute
    Musa, Hanny
    Zhao, Yihua
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
    Falchook, Gerald S.
    Kurzrock, Razelle
    Amin, Hesham M.
    Xiong, Wenyuan
    Fu, Siqing
    Piha-Paul, Sarina A.
    Janku, Filip
    Eskandari, Ghazaleh
    Catenacci, Daniel V.
    Klevesath, Manfred
    Bruns, Rolf
    Stammberger, Uz
    Johne, Andreas
    Bladt, Friedhelm
    Friese-Hamim, Manja
    Girard, Pascal
    El Bawab, Samer
    Hong, David S.
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1237 - 1246
12345